Sanofi

Sanofi-aventis

Sanofi-synthelabo

Elf Sanofi

Sanofi-syntelabo

Sanofi-synthlabo

Marco Baroni

Umberto Guzzi

Rosanna Cardamone

Pierre Casellas

Bernard Bourrie

Jacqueline Fournier

Sandrine Delbary-Gossart

Marco Landi

Francoise Bono

Tiziano Croci

Alessandra Ielmini

Antonina Giudice

Valentina Vercesi

Dino Nisato

Letizia Puleo

Vivian Mazza

Roberto Cecchi

Olaf Ritzeler

Philippe Soubrie

Françoise Bono

Domenico Badone

Roberta Avallone

Marco Zanchet

Michele Arnone

Casellas Pierre

The invention relates to disubstituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives of the general formula (I) where R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are such as defined in claim, to a method for preparing same, and to the therapeutic use of said compounds. 

Substituted 3-benzofuranyl-indol-2-one-3-acetamididopiperazine derivatives, preparation thereof, and therapeutic use thereof

The present disclosure relates to the use of a (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivative or (heterocycle-fused pyrrolidine)-(piperazinyl)-1-alkanone derivative or a pharmaceutically acceptable salt thereof as a p75 receptor antagonist in the treatment and/or prevention of overactive bladder.

Therapeutic use of P75 receptor antagonists

The disclosure relates to (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivatives and (heterocycle-fused pyrrolidine)-(piperazinyl)-1-alkanone derivatives of formula (I): wherein A, W, R2 and n are as defined in the disclosure, to the method of preparation thereof and the therapeutic use thereof.

(Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors

The disclosure relates to (heterocycle-tetrahydropyridine)(piperazinyl)-1-alkanone and (heterocycle-dihydropyrrolidine)(piperazinyl)-1-alkanone derivatives of formula (I): wherein A, B, m, n, W, and R2 are as defined in the disclosure; to the methods of preparing said derivatives, and to the therapeutic uses thereof.

(heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors

(Heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors

The present invention relates to derivatives of ((phenyl)-3,6-dihydropyridin-1-yl)(bridged piperazinyl)-1-alkanone derivatives and ((phenyl)-2,5-dihydropyrrol-1-yl) (bridged piperazinyl)-1-alkanone corresponding to Formula (I): in which the variables are as defined herein, to the preparation thereof and to the therapeutic use thereof.

Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors

The present invention relates to derivatives of 4-{2-[phenyl-3,6-dihydropyridin-1-yl]-2-oxoalkyl}-1-piperazin-2-one and 4-{2-[phenyl-2,5-dihydropyrrol-1-yl]-2-oxoalkyl}-1-piperazin-2-one having general formula (I): in which A, B, m, R3 and n are as defined herein. The invention also relates to the preparation thereof and to the therapeutic use thereof.

Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same

The present application discloses compounds of the formula: and pharmaceutical compositions containing same and their use for treating and preventing various pathologies, including obesity, appetite disorders, excess weight and diabetes.

Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof

The present invention relates to phenyl-alkyl piperazines of formula (I): in which A, R1, R2 and R3 are as defined herein, having TNF-modulating activity. The invention also relates to the preparation thereof, pharmaceutical compositions thereof, and to the therapeutic use thereof.

Phenyl-alkyl piperazines having TNF-modulating activity, preparation method, and therapeutic use thereof

The present invention relates to compounds of formula (III): in which

Aralkyltetrahydropyridines, their preparation and pharmaceutical compositions containing them

The present invention relates to compounds of formula (I): in which

Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same

The present invention relates to compounds of formula (I): in which X represents N or CH; Rrepresents a hydrogen or halogen atom or a CFgroup; Rand Rindependently represent a hydrogen atom or a methyl group; n is 0 or 1; A represents a condensed heterocyclic group of formula (w) where W completes an aromatic or saturated 6-membered ring system comprising one or two nitrogen atoms or else an aromatic or saturated 5-membered ring system comprising a nitrogen, oxygen or sulfur atom which are optionally substituted, and to their N-oxides and to their salts or solvates, to the pharmaceutical compositions and the medicaments comprising them and to a process for their preparation.

Phenyl- and pyridylpiperidines with TNF activity

The invention relates to the use of compounds of formula for the preparation of medicines designed for the treatment of neuronal and cerebral disorders. The invention also relates to the compounds of formula: a process for their preparation and the pharmaceutical compositions containing them.

Growing community of inventors

Vanzago, Italy

Marco Baroni